Literature DB >> 22837194

HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Benoît Vingert1, Daniela Benati, Olivier Lambotte, Pierre de Truchis, Laurence Slama, Patricia Jeannin, Moran Galperin, Santiago Perez-Patrigeon, Faroudy Boufassa, William W Kwok, Fabrice Lemaître, Jean-François Delfraissy, Jacques Thèze, Lisa A Chakrabarti.   

Abstract

HIV controllers are rare individuals who spontaneously control HIV replication in the absence of antiretroviral therapy. To identify parameters of the CD4 response that may contribute to viral control rather than merely reflect a persistently low viremia, we compared the T helper profiles in two groups of patients with more than 10 years of viral suppression: HIV controllers from the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) CO18 cohort (n = 26) and efficiently treated patients (n = 16). Cells specific for immunodominant Gag and cytomegalovirus (CMV) peptides were evaluated for the production of 10 cytokines and cytotoxicity markers and were also directly quantified ex vivo by major histocompatibility complex (MHC) class II tetramer staining. HIV controller CD4(+) T cells were characterized by a higher frequency of gamma interferon (IFN-γ) production, perforin(+)/CD107a(+) expression, and polyfunctionality in response to Gag peptides. While interleukin 4 (IL-4), IL-17, and IL-21 production did not differ between groups, the cells of treated patients produced more IL-10 in response to Gag and CMV peptides, pointing to persistent negative immunoregulation after long-term antiretroviral therapy. Gag293 tetramer-positive cells were detected at a high frequency (0.12%) and correlated positively with IFN-γ-producing CD4(+) T cells in the controller group (R = 0.73; P = 0.003). Tetramer-positive cells were fewer in the highly active antiretroviral therapy (HAART) group (0.04%) and did not correlate with IFN-γ production, supporting the notion of a persistent immune dysfunction in HIV-specific CD4(+) T cells of treated patients. In conclusion, HIV controllers maintained a population of highly efficient Th1 effectors directed against Gag in spite of a persistently low antigenemia, while patients treated in the long term showed a loss of CD4 effector functions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22837194      PMCID: PMC3457309          DOI: 10.1128/JVI.00056-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.

Authors:  C J Pitcher; C Quittner; D M Peterson; M Connors; R A Koup; V C Maino; L J Picker
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Clin Immunol       Date:  2004-03       Impact factor: 3.969

Review 3.  Functional signatures of protective antiviral T-cell immunity in human virus infections.

Authors:  Alexandre Harari; Valérie Dutoit; Cristina Cellerai; Pierre-Alexandre Bart; Renaud A Du Pasquier; Giuseppe Pantaleo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

4.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

5.  HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.

Authors:  Thomas J Scriba; Hua-Tang Zhang; Helen L Brown; Annette Oxenius; Norbert Tamm; Sarah Fidler; Julie Fox; Jonathan N Weber; Paul Klenerman; Cheryl L Day; Michaela Lucas; Rodney E Phillips
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.

Authors:  Ulrik Bak Dragsted; Amanda Mocroft; Stefano Vella; Jean-Paul Viard; Ann-Britt E Hansen; George Panos; Danielle Mercey; Ladislav Machala; Andrzej Horban; Jens D Lundgren
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226

8.  Detection of low-frequency human antigen-specific CD4(+) T cells using MHC class II multimer bead sorting and immunoscope analysis.

Authors:  Fabrice Lemaître; Manuelle Viguier; Min-Sun Cho; Jean-Marie Fourneau; Bernard Maillère; Philippe Kourilsky; Peter M Van Endert; Laurent Ferradini
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

9.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

Authors:  Alexandre Harari; Stéphanie Petitpierre; Florence Vallelian; Giuseppe Pantaleo
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

10.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  38 in total

1.  Cost-Effectiveness of Peer- Versus Venue-Based Approaches for Detecting Undiagnosed HIV Among Heterosexuals in High-Risk New York City Neighborhoods.

Authors:  Elizabeth R Stevens; Kimberly A Nucifora; Qinlian Zhou; Ronald Scott Braithwaite; Charles M Cleland; Amanda S Ritchie; Alexandra H Kutnick; Marya V Gwadz
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

Review 2.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

Review 3.  Advances in dendritic cell immunotherapies for HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Expert Opin Biol Ther       Date:  2014-08-21       Impact factor: 4.388

4.  A novel SIV gag-specific CD4(+)T-cell clone suppresses SIVmac239 replication in CD4(+)T cells revealing the interplay between antiviral effector cells and their infected targets.

Authors:  Victor I Ayala; Matthew T Trivett; Lori V Coren; Sumiti Jain; Patrick S Bohn; Roger W Wiseman; David H O'Connor; Claes Ohlen; David E Ott
Journal:  Virology       Date:  2016-03-25       Impact factor: 3.616

5.  Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression.

Authors:  Ankita Garg; Pratima Rawat; Stephen A Spector
Journal:  J Infect Dis       Date:  2014-09-18       Impact factor: 5.226

6.  Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome.

Authors:  Christian Selinger; Natasa Strbo; Louis Gonzalez; Lauri Aicher; Jeffrey M Weiss; G Lynn Law; Robert E Palermo; Monica Vaccari; Genoveffa Franchini; Eckhard R Podack; Michael G Katze
Journal:  Clin Vaccine Immunol       Date:  2014-10-01

7.  Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.

Authors:  Ivan Osokine; Laura M Snell; Cameron R Cunningham; Douglas H Yamada; Elizabeth B Wilson; Heidi J Elsaesser; Juan Carlos de la Torre; David Brooks
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

Review 8.  Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Authors:  Bernard J C Macatangay; Charles R Rinaldo
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

9.  In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.

Authors:  Brent E Palmer; C Preston Neff; Jonathan Lecureux; Angelica Ehler; Michelle Dsouza; Leila Remling-Mulder; Alan J Korman; Andrew P Fontenot; Ramesh Akkina
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

10.  Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Authors:  Clémence Granier; Emilie Battivelli; Camille Lécuroux; Alain Venet; Olivier Lambotte; Marion Schmitt-Boulanger; Constance Delaugerre; Jean-Michel Molina; Lisa A Chakrabarti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.